- 米国企業
- Cytosorbents Corp
Cytosorbents CorpCTSO
時価総額
$4299.9万
PER
| 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | |
| Total product sales | - | - | - | - | - | - | - | - | 23 | 39 | 40 | 29 |
| CytoSorb sales | - | - | - | - | - | - | - | - | 23 | 39 | 40 | 29 |
| Other sales | - | - | - | - | - | - | - | - | 220,100 | 110,400 | 111,867 | 787,201 |
| Grant income | - | - | - | - | - | - | - | - | 2 | 2 | 3 | 5 |
| Total revenue | - | - | - | - | - | - | - | 20 | 25 | 41 | 43 | 35 |
| Cost of revenue | - | - | - | - | - | - | - | 7 | 7 | 11 | 11 | 14 |
| Gross profit | 24,318 | 2 | 2 | 2 | 3 | 6 | 10 | 15 | 18 | 30 | 32 | 21 |
| Research and development | 51 | 54 | 56 | 2 | 4 | 5 | 4 | 8 | 12 | 9 | 16 | 15 |
| Professional Fees | 8 | 9 | 9 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 3 |
| Selling, general and administrative | - | 26 | 29 | 6 | 7 | 11 | 14 | 21 | 22 | 28 | 36 | 34 |
| Total operating expenses | 78 | 83 | 88 | 9 | 12 | 17 | 19 | 31 | 37 | 40 | 55 | 52 |
| Loss from operations | -4,436,767 | -3,490,834 | -4,713,231 | -7,278,792 | -9,303,659 | -11,492,125 | -9,842,598 | -15,584,928 | -18,974,064 | -10,370,334 | -22,744,745 | -31,521,879 |
| Interest (expense), net | -1,044,881 | -564,428 | -422,843 | -310,024 | 9,301 | -231,805 | -749,076 | -1,461,045 | -1,033,661 | -1,201,067 | 28,007 | 132,597 |
| Gain (loss) on foreign currency transactions | - | - | - | - | -507,276 | -358,077 | 1 | -784,752 | -350,365 | 3 | -2,577,913 | -2,448,583 |
| Miscellaneous Income | - | - | - | - | - | - | - | - | - | - | - | -67,303 |
| Total other income (expense), net | -1,044,881 | -564,428 | -422,843 | -2,428,522 | 847,315 | -765,300 | 705,060 | -2,245,797 | -1,384,026 | 1 | -2,549,906 | -2,383,289 |
| Loss before benefit from income taxes | -5,481,648 | -4,055,262 | -5,136,074 | -9,707,314 | -8,456,344 | -12,257,425 | -9,137,538 | -17,830,725 | -20,358,090 | -8,964,262 | -25,294,651 | -33,905,168 |
| Benefit from income taxes | -547,318 | -391,756 | -458,279 | -385,642 | -324,606 | -318,550 | -676,739 | -619,546 | -1,092,446 | -1,127,074 | -736,003 | -1,092,585 |
| Net loss attributable to common stockholders | -8,568,692 | -6,174,918 | -7,073,315 | -18,588,345 | -8,131,738 | -11,938,875 | -8,796,530 | -17,211,179 | -19,265,644 | -7,837,188 | -24,558,648 | -32,812,583 |
| Earnings Per Share, Basic | - | - | - | - | - | - | - | - | - | - | -0.57 | -0.75 |
| Earnings Per Share, Diluted | - | - | - | - | - | - | - | - | - | - | -0.57 | -0.75 |
| Net loss | -5,481,648 | -3,663,506 | -4,677,795 | -9,321,672 | -8,131,738 | -11,938,875 | -8,460,799 | -17,211,179 | -19,265,644 | -7,837,188 | -24,558,648 | -32,812,583 |
| Foreign currency translation adjustment | - | - | -43,325 | 283,688 | 356,616 | 314,367 | -1,259,669 | 649,160 | 237,803 | -2,260,056 | 2 | 2 |
| Comprehensive loss | - | -3,676,168 | -4,721,120 | -9,037,984 | -7,775,122 | -11,624,508 | -9,720,468 | -16,562,019 | -19,027,841 | -10,097,244 | -22,298,985 | -31,008,973 |